

futurecast

PRESS RELEASE

CE-certified RougeN™

COVID-19 vaccine immune response test kit

09 NOV 2021

Hong Kong

01



COVID TESTING

Futurecast to commercialise semi-quantitative CE-certified rougeN™ COVID-19 Vaccine Immune Response Test Kit following strategic partnership with US-based RougeN Diagnostics Inc.

- Recent data reveals 39.2% of the world's population are fully vaccinated. A full vaccination, however, does not grant complete immunity to COVID-19 and response to vaccinations varies.
- As the duration of protective immunity after vaccination fluctuates, it is critical to provide individual accurate insights into their immune response as they engage socially post vaccination.
- Scientific evidence indicates IgG neutralising antibody testing as the best proxy for immune status.

Futurecast Ltd, an end-to-end screening solutions at Point of Need (PON) provider, has entered into a strategic distribution agreement with US-based RougeN Diagnostics Inc. to commercialise its CE-certified rougeN™ Immune Response Test Kit. The rougeN™ test kit has been developed to measure the concentration of neutralising antibodies to COVID-19 or the level of antibodies to the receptor-binding domain of the spike protein, which is a major component of the COVID-19 vaccine. The test offers a non-invasive solution to neutralising antibody testing and provides a reliable (98.47% accuracy) semi-quantitative result within 15 minutes. It is simple and cost-effective.



© rougeN™ Images

The RougeN Immune Response Test Kit

can be used to monitor IgG neutralising antibody responses post-infection or vaccination. It gives an indication on immunity status, helping individuals to make more informed decisions about their social interactions, and contributing to maintain public safety. Futurecast will make rougeN™ available to client labs as well as distribution partners in Europe, Middle East & Africa.

"Large-scale immune response testing helps understand the dynamics of the pandemic, and evolve more effective responses, particularly in the context of the proliferation of variants. Among other benefits, monitoring antibody levels helps determine vaccine durability, adapt vaccination strategies, and allows individuals to enjoy the benefits of increased social activity as social restrictions ease. Those who are not immune may opt to be more cautious, or be allowed an additional vaccine shot, subject to local regulations," said Cecile Goulet, Chief Clinical Innovation Officer at Futurecast.

Yves Alavo, Founder & CEO of Futurecast adds: "This strategic partnership to lead the rollout of the rougeN™ test across these markets fully supports our vision to power health surveillance by making the most effective rapid screening innovations available to healthcare providers and individuals alike. While the RougeN™ test is already CE-certified it is currently under review by UK Department of Health & Social Care".

Enquiries —

more@wefuturecast.com

About Futurecast Ltd.

We are accelerating the advent of a decentralised and democratised healthcare ecosystem by simplifying access to innovation in care and empowering healthcare and non-healthcare operators. As an unconventional care company, our vision is to become the largest contributor to the

state of preparedness of the world against health threats.

www.wefuturecast.com

About RougeN Diagnostic Inc.

We are an innovative, USA-based biotech company specialised in rapid tests for emerging infectious diseases - and sold worldwide. Through innovative research and collaboration with public health institutions, governments and medical researchers, RougeN Diagnostics provides mission-critical testing for patients and healthcare providers. Our lab partner operates in a fully HIPAA compliant environment.

www.rougendiagnosics.com



CONTINUE READING DIGITALLY AND DISCOVER MORE STORIES

visit our website www.wefuturecast.com/insight/ce-certified-rougen